Dr Reddy’s Laboratories Q2 Results: Net profit drops 9.5% to ₹1,342 crore on acquisition cost, revenue up 16.5% YoY
The drugmaker’s total revenue from operations in the second quarter of current fiscal rose 16.5 per cent to ₹8,016 crore.
India's Dr Reddy's Q2 profit drops on acquisition cost, impairment charge
By Rishika Sadam and Kashish Tandon HYDERABAD/BENGALURU (Reuters) -Indian generic drugmaker Dr Reddy's Laboratories' second-quarter profit was hit by one-time charges related to its joint venture with Nestle India and Nicotinell acquisition,
Dr Reddy's Labs Q2 Results: Profit falls 15% YoY to Rs 1,255 crore, revenue up 17%
Healthcare major Dr Reddy's Labs on Tuesday reported 15% drop in its consolidated net profit at Rs 1,255 crore in the second quarter. It was Rs 1,480 crore in the year-ago quarter.Revenue from operations in the same period stood at Rs 8,
Dr Reddy's Labs Q2 Preview: Profits may decline 7%, revenues to rise 12%
Dr Reddy's Lab’s average revenue will potentially increase 12 per cent Y-o-Y to Rs 7,734 crore as against Rs 6,902 crore in Q2FY24. On a quarterly basis, the revenues may rise by 0.4 per cent. The pharma company registered revenues of Rs 7,696 crore in the June quarter of FY25.
Dr Reddy’s likely to post dip in net profit in Q2, FY25
Pharma major Dr Reddy’s Laboratories is expected to post a decline in net profit in the second quarter of current fiscal year ended September 30, 2024 driven by a tardy growth in North America market with an increase in the top line in the numbers to be announced on Tuesday,
Dr. Reddy’s Q2 net slips to ₹1,342 cr. on record sales
Dr. Reddy’s Laboratories consolidated net profit declined 9.5% for the September quarter to ₹1,341.9 crore compared to ₹1,482.2 crore in the year earlier period even as the generic drugmaker reported revenue from operations raced past ₹8,000 crore for the first time.
Q2 results today: Titan, Mazagon, and Dr Reddy's among 63 to post earnings
GAIL India, Oil India, Merger Paints, Mankind Pharma, and Saregama will be releasing their earnings report for the July-September quarter on Nov 5
India's Dr Reddy's misses Q2 profit view on weak pricing in North America
(Reuters) -Indian generic drugmaker Dr Reddy's Laboratories reported a second-quarter profit that missed analysts' expectations on Tuesday, weighed down by pricing pressure in a competitive North American market,
Dr Reddy's Q2 net profit falls 9.3 pc to Rs 1,341.5 cr; revenue up 16.5 pc
Pharma major Dr Reddy’s Laboratories (DRL) on Tuesday reported a 9.35 per cent decline in its consolidated net profit to Rs 1,341.5 crore for the second quarter ended September 2024. DRL had posted a net profit of Rs 1,
cnbctv183h
Healthcare major Dr Reddy's Q2 net profit falls, revenue gains momentum
Healthcare major Dr Reddy's Laboratories reported a 15% decline in its consolidated net profit, totalling ₹1,255 crore ...
DRL Q2 net falls 15% despite revenue surge
HYDERABAD: Pharma major Dr Reddy's Laboratories on Tuesday reported a 15% drop in ... Consolidated net profit for Q2 ...
Dr Reddy’s Q2 profits decline 9%, revenue grows 17%
Pharma major Dr Reddy’s Laboratories’ net profit declined 9 per cent at ₹1,341 crore in the second quarter ended ...
Dr. Reddy's Laboratories Limited (RDY) Q2 2025 Earnings Call Transcript
Ladies and gentlemen, good day, and welcome to the Quarter Two FY 2025 Earnings Conference Call of Dr. Reddy's Laboratories Limited. As a reminder, all participants' lines will be in the listen-only ...
Dr Reddy's R&D expenses to stay around 8.5% in FY25, to launch key biosimilar in 2027
Much like the trend in the domestic pharma industry, Dr Reddy's Laboratories is investing heavily in research and development aimed at ramping up the biosimilars, generics, and biologics segments.